On June 8, 2009 (May 16, 2009 lunar calendar), Beijing Kexing Company officially started mass production of A (H1N1) influenza vaccine. On June 8, 2009, Beijing Kexing Company officially started mass production of A (H1N1) influenza vaccine. On June 8, 2009, researchers were preparing batches of virus seeds. On the same day, the H1N1 influenza vaccine production strain NYMCX-179A from the United States arrived in Beijing from the United States. After customs clearance, inspection and quarantine and other procedures, it was sent to Beijing Kexing Biological Products Co., Ltd. Beijing Kexing, which has completed the clinical research of the vaccine, started the preparation of the seed batch of the strain that night, which marked the official start of the mass production of the A (H1N1) influenza vaccine, and is expected to produce the first batch of vaccines by the end of July. As the only enterprise in our country with the qualification for the production of pandemic influenza vaccines, Beijing Kexing Biological Products Co., Ltd. obtained the A (H1N1) influenza vaccine production strain from the US CDC on the 8th, which means that the mass production of the A (H1N1) influenza vaccine "Paneraifu" in our country has officially started. On the 8th, it was learned from the Ministry of Health that the H1N1 influenza vaccine strains identified by the World Health Organization were delivered to Beijing on the afternoon of the 8th by the US Centers for Disease Control and Prevention and the British Biological Products Testing Institute. These vaccine strains were immediately sent to relevant vaccine manufacturers. Previously, the vaccine strains provided by the British Biological Products Testing were shipped to Hualan Bioengineering joint stock company and Dalian Yalifeng Biopharmaceutical Co., Ltd on June 3 and June 5 respectively. Yin Weidong, general manager of Beijing Kexing Company, said that with the strong support of the national H1N1 influenza joint prevention and control guarantee team, the General Administration of Customs and the General Administration of Quality Supervision, Inspection and Quarantine of the People's Republic of China and other departments, the strain NYMCX-179A for the production of A H1N1 influenza vaccine from the CDC of the United States arrived in Beijing Kexing on the evening of the 8th. Beijing Kexing quickly started the batch preparation of virus seeds after getting the strain. It is understood that the production of a single batch of vaccine needs to go through steps such as virus vaccination, virus culture, virus inactivation, purification, proportioning, sub-packaging and batch issuance before it can finally be put into use. In order to achieve the protective effect of the vaccine and save antigens, Beijing Kexing adopted the production process of adjuvant vaccine for A H1N1 influenza vaccine this time. If all goes well, the first batch of vaccines will be produced by the end of July. Beijing Kexing's existing pandemic influenza vaccine production line has a designed annual capacity of 20 million to 30 million, making it the only enterprise in our country with pandemic influenza vaccine production qualifications. Due to the huge demand for pandemic influenza vaccines, Beijing Kexing's production capacity is difficult to fully meet the needs of the country and the public. In order to provide protection to as many people as possible, Beijing Kexing decided to form an alliance with several domestic seasonal influenza vaccine manufacturers and share the key technologies for pandemic influenza vaccine production formed by Beijing Kexing's relevant research institutes since 2004 with partners, and jointly undertake the production of the vaccine "Panerlaifu". Yin Weidong told reporters that the production and verification of "Panerlaifu" will be carried out in strict accordance with the "Regulations for the Manufacturing and Verification of Pandemic Influenza Virus Inactivated Vaccines" approved by the State Food and Drug Administration. The State Food and Drug Administration has also issued the "Emergency Work Plan for Special Approval of Pandemic Influenza Vaccines" in a timely manner, so that the cooperative production of vaccines has legal basis, to ensure the scientific, legal, orderly and efficient production of vaccines, and to ensure the safety of vaccine use. In 2004, Beijing Kexing cooperated with the Chinese Center for Disease Control and Prevention to start the research of pandemic influenza prototype vaccines with the support of the Ministry of Science and Technology and the Ministry of Health, and built a new automated sub-packaging line with the support of the National Development and Reform Commission. In 2008, the vaccine successfully completed clinical research and received a production approval from the State Food and Drug Administration. Beijing Kexing Company has been committed to the research and development, production and sales of human vaccines and related products. Currently listed products include the inactivated hepatitis A vaccine "Hilleford", the hepatitis A and B combined vaccine "Bellefort", etc. Comments: China is at the forefront of vaccine preparation in the fight against the infectious disease of influenza A